ManageChatDiscover
262698

Evaluation of In vitro Activity of Cefiderocol and Ceftolozane-Tazobactam against Extended-Spectrum β-Lactamase–Producing Coliform and Multidrug Resistant Acinetobacter baumannii

Article

Last updated: 05 Jan 2025

OverviewSimilar Items

Subjects

-

Tags

Antimicrobial agents

Abstract

Background: A worrisome escalation in multidrug-resistant (MDR) Gram-negative bacterial infections which are accompanied with worse outcomes due to inadequate treatment options. There is an imperative requirement to explore new antimicrobials to oppose these resistant strains. Objectives: Assessment of antibacterial activity of Cefiderocol and Ceftolozane-Tazobactam against ESBL–Producing coliform and MDR A. baumannii and P. aeruginosa. Methodology: A total of 332 clinical samples were obtained from surgical ICU cases. Pathogenic microorganisms were identified. Antibiotic susceptibility was done for gram negative isolates. Third-generation cephalosporins resistant coliforms were screened for ESBL detection. Ceftolozane-Tazobactam and Cefiderocol activity on ESBL coliform and MDR P. aeruginosa and A. baumannii isolates was investigated. Results: The susceptibility of both ESBL E. coli, K. pneumoniae, MDR P. aeruginosa, and A. baumannii to ceftolozane/tazobactam was 77%, 70% ,63% and 58% respectively. ESBL E. coli and K. pneumonaie    exhibited MIC 50/90 value of (0.19/0.25μg/mL) and (0.25/0.5μg/mL) for ceftolozane/tazobactam respectively.  MDR P. aeruginosa   showed MIC 50/90 value (2/4μg/mL). MDR A. baumannii exhibited high MIC 50/90   value (16/24μg/mL).  Cefiderocol was 100% effective against most isolates with different MIC 50/90 values. For ESBL-E. coli and K. pneumoniae, the MIC 50/90 value was (0.5/1.5μg/mL). For MDR P. aeruginosa and A. baumannii, the MIC 50/90 value was (0.75/2μg/mL) and (0.25/2μg/mL) respectively. Conclusion: Cefiderocol exhibits superior activity against ESBL coliform and MDR   A. baumannii, P. aeruginosa compared to ceftolozane-Tazobactam.

DOI

10.21608/ejmm.2022.262698

Keywords

Ceftolozane-tazobactam, Cefiderocol, ESBL Enterobacterales, P. aeruginosa

Authors

First Name

Eman

Last Name

hegazy

MiddleName

elsayed

Affiliation

medical microbiology and immunology department ,faculty of medicine, Tanta university

Email

eman.hegazi@med.tanta.edu.eg

City

Tanta

Orcid

0000-0001-9263-1894

First Name

Shaimaa

Last Name

Zahra

MiddleName

Waheed

Affiliation

1. Department of Medical Microbiology and Immunology, Faculty of Medicine, Tanta University

Email

shaimaawaheed137@gmail.com

City

-

Orcid

-

First Name

Sarah M.

Last Name

Shoeib

MiddleName

-

Affiliation

2. Department of Clinical Pathology, Faculty of Medicine, Tanta University

Email

sara.shoeib@med.tanta.edu.eg

City

-

Orcid

-

First Name

Marwa S.

Last Name

Taha

MiddleName

-

Affiliation

Department of Medical Microbiology and Immunology, Faculty of Medicine, Tanta University

Email

marwa.taha@med.tanta.edu.eg

City

-

Orcid

-

Volume

31

Article Issue

4

Related Issue

36977

Issue Date

2022-10-01

Receive Date

2022-10-01

Publish Date

2022-10-01

Page Start

123

Page End

129

Print ISSN

1110-2179

Online ISSN

2537-0979

Article File

EJMM_Volume 31_Issue 4_Pages 123-129.pdf

PDF . 386.0kB

Link

https://ejmm.journals.ekb.eg/article_262698.html

Detail API

https://ejmm.journals.ekb.eg/service?article_code=262698

Order

262,698

Type

New and original researches in the field of Microbiology.

Type Code

2,038

Publication Type

Journal

Publication Title

Egyptian Journal of Medical Microbiology

Publication Link

https://ejmm.journals.ekb.eg/

MainTitle

Evaluation of In vitro Activity of Cefiderocol and Ceftolozane-Tazobactam against Extended-Spectrum β-Lactamase–Producing Coliform and Multidrug Resistant Acinetobacter baumannii

Details

Type

Article

Created At

23 Jan 2023